Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial.

Autor: Borchmann P; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany. Electronic address: peter.borchmann@uk-koeln.de., Ferdinandus J; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany., Schneider G; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany., Moccia A; Swiss Group for Clinical Cancer Research, Bern, Switzerland; Oncology Institute of Southern Switzerland, EOC, Medical Oncology, Bellinzona, Switzerland., Greil R; 3rd Medical Department, Paracelcus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Salzburg, Austria; Arbeitsgemeinschaft Medikamentöse Tumortherapie, Salzburg, Austria., Hertzberg M; Prince of Wales Hospital Department of Haematology and University NSW, Sydney, NSW, Australia; Australasian Leukaemia & Lymphoma Group, Melbourne, VIC, Australia., Schaub V; University of Tübingen, Tübingen, Germany., Hüttmann A; Department of Haematology, University Hospital, University Duisburg-Essen, Essen, Germany., Keil F; Department of Haematology, Hanusch Krankenhaus, Vienna, Austria., Dierlamm J; University Hospital Hamburg-Eppendorf, Hamburg, Germany., Hänel M; Department III of Internal Medicine, Klinikum Chemnitz, Chemnitz, Germany., Novak U; Swiss Group for Clinical Cancer Research, Bern, Switzerland; Department of Medical Oncology, University Hospital Bern, Bern, Switzerland., Meissner J; Department of Hematology and Oncology, University of Heidelberg, Heidelberg, Germany., Zimmermann A; Department of Hematology and Oncology, Klinikum Leverkusen, Leverkusen, Germany., Mathas S; Department of Hematology, Oncology, and Cancer Immunology, Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Berlin, Germany; Humboldt University of Berlin, Berlin Institute of Health, Berlin, Germany; Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association (MDC), Biology of Malignant Lymphomas, Berlin, Germany; Experimental and Clinical Research Center (ECRC), a joint cooperation between Charité and MDC, Berlin, Germany., Zijlstra JM; Department of Hematology, Amsterdam UMC, Vrije Universiteit, Cancer Center, Amsterdam, Netherlands., Fosså A; Department of Oncology, Oslo University Hospital, Oslo, Norway; Nordic Lymphoma Group, University Hospital of Ulm, Ulm, Germany., Viardot A; Department of Internal Medicine III, University Hospital of Ulm, Ulm, Germany., Hertenstein B; Department of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany., Martin S; Department of Haematology and Oncology, Robert Bosch Hospital, Stuttgart, Germany., Giri P; Department of Haematology and Bone Marrow Transplant, Royal-Adelaide-Hospital, Adelaide, SA, Australia., Scholl S; Klinik für Innere Medizin II, Jena University Hospital, Jena, Germany., Topp MS; Department of Internal Medicine II, Hematology and Oncology, University Hospital Wuerzburg, Wuerzburg, Germany., Jung W; Department of Haematology and Oncology, Göttingen, Germany., Vucinic V; Department of Hematology, Cellular Therapy, Hemostaseology and Infectious Diseases, University of Leipzig, Leipzig, Germany., Beck HJ; Department of Medicine III, Universitätsmedizin Mainz, Mainz, Germany., Kerkhoff A; Department for Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Muenster, Muenster, Germany., Unger B; Hämatologie, Onkologie und Tumorimmunologie, HELIOS Klinikum Berlin-Buch, Berlin, Germany., Rank A; Department of Internal Medicine II, University Hospital Augsburg, Augsburg, Germany., Schroers R; Department of Hematology and Oncology, Universitätsklinikum Knappschaftskrankenhaus Bochum, Ruhr-University Bochum, Germany., Zum Büschenfelde CM; Clinic for Hematology, Oncology, Immunology and Palliative Medicine, Vincentius-Deaconry Clinics gAG, Karslruhe, Germany., de Wit M; Clinic for Hematology, Oncology and Palliative Medicine, Vivantes Klinikum Neukölln, Berlin, Germany., Trautmann-Grill K; Medical Clinic I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany., Kamper P; Nordic Lymphoma Group, University Hospital of Ulm, Ulm, Germany; Department of Hematology, University Hospital of Aarhus, Aarhus, Denmark., Molin D; Nordic Lymphoma Group, University Hospital of Ulm, Ulm, Germany; Department of Immunology, Genetics and Pathology, Cancer Immunotherapy, Uppsala University, Uppsala, Sweden., Kreissl S; Ordensklinikum Linz Elisabethinen, Linz, Austria., Kaul H; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany., von Tresckow B; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany; Department of Haematology, University Hospital, University Duisburg-Essen, Essen, Germany., Borchmann S; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany., Behringer K; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany., Fuchs M; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany., Rosenwald A; Institute for Pathology, University Hospital Würzburg, Würzburg, Germany., Klapper W; Karl Lennert Cancer Center, University Hospital Schleswig-Holstein, Kiel, Germany., Eich HT; Department of Radiotherapy, University Hospital of Muenster, Muenster, Germany., Baues C; Department of Radiation Oncology, University Hospital of Ruhr-Universität Bochum, Marien Hospital Herne, Herne, Germany., Zomas A; Global Medical Lead for Lymphoma & Leukemia at Takeda Oncology, Cambridge, MA, USA., Hallek M; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany., Dietlein M; Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Cologne, Germany., Kobe C; Department of Nuclear Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Cologne, Germany., Diehl V; Faculty of Medicine, University of Cologne, Cologne, Germany; Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University Hospital, Düsseldorf, Germany; German Hodgkin Study Group, Cologne, Germany.

Publikováno v: Lancet (London, England) [Lancet] 2024 Jul 27; Vol. 404 (10450), pp. 341-352. Date of Electronic Publication: 2024 Jul 03.

The impact of MICB mismatches in unrelated haematopoietic stem cell transplantation.

Autor: Amann EM; Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Ulm, Germany.; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany., Gowdavally S; Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Ulm, Germany., Tsamadou C; Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Ulm, Germany.; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany., Platzbecker U; Department of Hematology/Oncology, University of Leipzig, Leipzig, Germany., Sala E; Department of Internal Medicine III, University of Ulm, Ulm, Germany., Wagner-Drouet E; Department of Medicine III, Johannes Gutenberg-University Mainz, Mainz, Germany., Valerius T; Section for Stem Cell Transplantation and Immunotherapy, Department of Medicine II, Christian Albrechts University, Kiel, Germany., Kröger N; Department of Stem Cell Transplantation, University Hospital Hamburg Eppendorf, Hamburg, Germany., Wulf G; Department of Hematology/Oncology, Georg-August-University Göttingen, Göttingen, Germany., Einsele H; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany., Thurner L; Department Internal Medicine I, Universitätsklinikum des Saarlandes, Homburg, Germany., Schaefer-Eckart K; Medical Clinic 5: Hematology, Oncology, Nuremberg Hospital, Nuremberg, Germany., Freitag S; Department of Medicine III, Hematology/Oncology/Palliative Care, Rostock University Medical Center, Rostock, Germany., Casper J; Department of Oncology and Hematology, Klinikum Oldenburg, University Clinic, Oldenburg, Germany., Dürholt M; Hematology/Oncology, Evangelic Clinic Essen-Werden, Essen, Germany., Kaufmann M; 2nd Department of Internal Medicine, Oncology and Hematology, Robert Bosch Hospital Stuttgart, Stuttgart, Germany., Hertenstein B; Hematology/Oncology, Klinikum Bremen-Mitte, Bremen, Germany., Klein S; Universitätsmedizin Mannheim, Med. Klinik III, Mannheim, Germany., Ringhoffer M; Medizinische Klinik III, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany., Frank S; DRST - German Registry for Stem Cell Transplantation, Ulm, Germany., Saal T; Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Ulm, Germany.; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany., Schmid-Möglich A; Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Ulm, Germany.; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany., Neuchel C; Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Ulm, Germany.; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany., Schrezenmeier H; Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Ulm, Germany.; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany., Mytilineos J; DRST - German Registry for Stem Cell Transplantation, Ulm, Germany.; ZKRD - Zentrales Knochenmarkspender-Register für Deutschland, German National Bone Marrow Donor Registry, Ulm, Germany., Fürst D; Institute of Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service, Baden Wuerttemberg - Hessen, Ulm, and University Hospital Ulm, Ulm, Germany.; Institute of Transfusion Medicine, University of Ulm, Ulm, Germany.

Publikováno v: HLA [HLA] 2024 Jun; Vol. 103 (6), pp. e15584.

Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries.

Autor: Lübke J; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany., Christen D; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany & Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Aachen, Germany., Schwaab J; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany., Kaiser A; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany & Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Aachen, Germany., Naumann N; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany., Shoumariyeh K; Department of Medicine I, Medical Center- University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany and German Cancer Consortium (DKTK), Partner Site Freiburg, Freiburg, Germany., Jentzsch M; Clinic and Policlinic for Hematology and Cellular Therapy, University of Leipzig Medical Center, Leipzig, Germany., Sockel K; Medical Department I, University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany., Schaffrath J; Department of Internal Medicine IV, Hematology and Oncology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany., Ayuk FA; Department of Stem Cell Transplantation with Research Department Cell and Gene Therapy University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Stelljes M; Department of Medicine A/Hematology and Oncology, University of Muenster, Münster, Germany., Hilgendorf I; Universitätsklinikum Jena, Klinik für Innere Medizin II, Abteilung für Hämatologie und Internistische Onkologie, Jena, Germany., Sala E; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany., Kaivers J; Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Schönland S; Department of Internal Medicine V, Division of Hematology/Oncology, Heidelberg University Hospital, Heidelberg, Germany., Wittke C; Department of Medicine, Clinic III, Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, Rostock, Germany., Hertenstein B; Klinikum Bremen-Mitte, Bremen, Germany., Radsak M; 3rd Department of Medicine, Johannes Gutenberg University Medical Center, Mainz, Germany., Kaiser U; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany., Brückl V; Department of Internal Medicine 5, Hematology and Oncology, University Hospital Erlangen, Erlangen, Germany., Kröger N; Department of Stem Cell Transplantation with Research Department Cell and Gene Therapy University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Brümmendorf TH; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany & Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Aachen, Germany., Hofmann WK; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany., Klein S; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany., Jost E; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany & Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Aachen, Germany., Reiter A; Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany. andreas.reiter@medma.uni-heidelberg.de., Panse J; Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany & Center for Integrated Oncology (CIO), Aachen, Bonn, Cologne, Düsseldorf (ABCD), Aachen, Germany.

Publikováno v: Leukemia [Leukemia] 2024 Apr; Vol. 38 (4), pp. 810-821. Date of Electronic Publication: 2024 Mar 06.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.

Autor: Fuchs M; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Jacob AS; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Kaul H; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Kobe C; Department of Nuclear Medicine, University of Cologne, Cologne, Germany., Kuhnert G; Nuclear Medicine Siegen I Kreuztal, Siegen, Germany., Pabst T; Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland., Greil R; IIIrd Medical Department, Paracelcus Medical University and Salzburg Cancer Research Institute, Salzburg, Austria.; Salzburg Cancer Research Institute and AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie), Salzburg, Austria., Bröckelmann PJ; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Topp MS; Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany., Just M; Dres. med. Just/Düwel/Riesenberg/Steinke/Schäfer, Studiengesellschaft, Bielefeld, Germany., Hertenstein B; Department of Internal Medicine I, Klinikum Bremen Mitte, Bremen, Germany., Soekler M; Onkology, Spital Thun, Switzerland, formerly University of Tübingen, Tübingen, Germany., Vogelhuber M; Medizinische Klinik III, Universitätsklinik Regensburg, Regensburg, Germany., Zijlstra JM; Department of Hematology, Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands., Keller UB; Department of Internal Medicine III, Klinikum 'Rechts der Isar', Munich, Germany., Krause SW; Department of Internal Medicine 5, Haematology/Oncology, Uniklinikum Erlangen, Erlangen, Germany., Dührsen U; Department of Haematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Meissner J; University of Heidelberg, Heidelberg, Germany., Viardot A; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany., Eich HT; Department of Radiotherapy, University Hospital of Muenster, Muenster, Germany., Baues C; Department of Radiotherapy, University of Cologne, Cologne, Germany., Diehl V; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Rosenwald A; Institute of Pathology, Julius Maximilian University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany., Buehnen I; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., von Tresckow B; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany.; Department of Haematology and Stem Cell Transplantation, West German Cancer Center and German Cancer Consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Dietlein M; Department of Nuclear Medicine, University of Cologne, Cologne, Germany., Borchmann P; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Engert A; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany., Eichenauer DA; German Hodgkin Study Group (GHSG), Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, University of Cologne, Cologne, Germany. dennis.eichenauer@uk-koeln.de.

Publikováno v: Leukemia [Leukemia] 2024 Jan; Vol. 38 (1), pp. 160-167. Date of Electronic Publication: 2023 Oct 16.